Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Nevada for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Nevada only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Nevada (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Nasim Daoud (NPI 1518117795)

Field	Value
Entity Type	Individual
Organization	Nasim Daoud
Address	8420 S Eastern Ave Ste 101
City	Las Vegas
State	NV
ZIP	89123
Taxonomy	Rheumatology Physician
NPI Enumerated	September 24, 2008

Payer Source	Total Paid
Medicare	$1.3M
Medicaid	$0

Key Findings

NASIM DAOUD is effectively a single-payer Medicare practice: lifetime Medicare revenue is reported as $1.3M while there is no Medicaid billing on file, indicating the provider’s commercial/Medicaid-facing activity is either minimal or not captured in state Medicaid claims. This creates a concentrated exposure to Medicare reimbursement dynamics for revenue planning and contracting.

Revenue concentration is high: the precomputed top 3 Medicare codes account for 87.2% of this provider's total Medicare revenue, signaling that a small set of administered biologic and infusion drugs dominate the practice’s billing and cashflow. Operational and procurement decisions are likely driven by access to, inventory of, and reimbursement for these specific injectable therapies.

The practice’s top Medicare revenue driver is J0129 (abatacept) with $579.5K or 44.1% of Medicare revenue; this code ranks #176 of 1221 providers nationally (86th percentile), which positions the provider as an above-typical but not dominant national participant for abatacept administration. High abatacept revenue suggests a significant in-office biologic infusion or injection service line consistent with rheumatology disease-modifying therapy delivery.

J0717 (certolizumab pegol) is the second largest contributor at $411.2K (31.3% of Medicare revenue) and ranks #140 of 848 providers nationally (84th percentile); like J0129, this places the provider well above median peers in use of this biologic but still among a broad group of similar-volume administrators rather than as a top national outlier. Together with J0129 and J1602, these biologic/injection codes are the core clinical services generating the bulk of Medicare revenue.

J1602 (golimumab IV) contributes $156.3K (11.9% of Medicare revenue) and ranks #487 of 1041 providers nationally (53th percentile), indicating a near-average national standing for that specific intravenous biologic. The mix of high-ranking subcutaneous/IV biologic codes plus infusion administration codes (e.g., 96365, 96401, 96413) signals the practice operates an infusion/administration workflow in addition to office-based E/M care.

Visit-level E/M codes are present but constitute a modest share of revenue: 99214 generates $60.1K (4.6% of Medicare revenue) and ranks in the 95th percentile nationally for volume, indicating a relatively high E/M visit intensity compared with peers even though E/M revenue is small relative to biologic drug revenue. This pattern is typical for rheumatology practices that bill for both specialist visits and costly injectable biologics.

Several administration/infusion codes show above-typical volumes (e.g., 96372 ranks in the 98th percentile and 96365 in the 88th percentile), reinforcing that in-office injections and IV infusions are central operational activities. While these codes contribute smaller dollar amounts individually, together they support the delivery model required for the high-value biologic drugs driving revenue.

Tenure: the NPI was enumerated on 2008-09-24 (~18 years ago), indicating long-standing Medicare participation. This longevity supports the observed sustained utilization of biologic therapies and established referral/infusion workflows rather than a recent shift in service mix.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

18 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	17,560	$30	$579.5K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	102,810	$1	$411.2K
J1602	Injection, golimumab, 1 mg, for intravenous use	14,210	$10	$156.3K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	720	$80	$60.1K
J7329	Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg	4,480	$10	$31.4K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	290	$50	$15.4K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	290	$50	$13.8K
20610	In this procedure, the provider inserts a needle through the skin of a patient and into a major joint or bursa and then uses the syringe attachment to the needle to remove fluid or he may inject a…	280	$50	$13.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	120	$100	$11.5K
99204	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider…	70	$110	$7.1K

Showing 1–10 of 18

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 18 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Nevada Distribution

Nasim Daoud — 5 of 17 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Nevada

Full comparison — all codes billed, vs. state median

18 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	1	10	8,300	$30	$297.2K
J0717	1	10	72,600	$1	$247.5K
J1602	1	10	12,250	$10	$122K
J7329	3	10	2,050	$10	$31.8K
96413	47	70	210	$100	$23.7K
99214	230	3,610	110	$80	$19K
99213	1,571	3,500	80	$60	$10K
96365	15	90	110	$50	$9.7K
96401	3	30	100	$60	$7.1K
99204	511	2,010	30	$110	$5.8K

Showing 1–10 of 18

Related Providers

Other providers that share a Tax Identification Number (TIN) with Nasim Daoud, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Seventh-day Adventists Loma Linda University Medical Center	CA	General Acute Care Hospital	$0	$253.4M
Faculty Physicians And Surgeons Of Llusm	CA	Pediatrics Physician	$0	$66.4M
Faculty Physicians And Surgeons Of Llusm	CA	Surgery Physician	$0	$54.9M
Shil Patel	VA	Ophthalmology Physician	$6.1M	$0
Khaled Tawansy	CA	Ophthalmology Physician	$2.8M	$2.4M
Homayoun Tabandeh	CA	Ophthalmology Physician	$5.1M	$6.8K
Daniel Taheri	CA	Dermatology Physician	$3.3M	$7.4K
Daniel Esmaili	CA	Ophthalmology Physician	$2.7M	$2.2K
Victor Shi	CA	Vascular & Interventional Radiology Physician	$2.2M	$280
Ari Katerelos	GU	Radiation Oncology Physician	$2.1M	$0

Nearby Providers

Other providers in the same ZIP code as Nasim Daoud, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Sl Consulting LLC	NV	Clinical Medical Laboratory	$1.7M	$11.6M
Mountain View Family Services	NV	Behavior Analyst	$0	$11.6M
Children's Bone And Spine Surgery, LLP	NV	Specialist	$0	$5.9M
Ulrike Pasternak	NV	Family Nurse Practitioner	$4M	$0
Caroline A. Bobbett, Dds Apc	NV	Dentist	$0	$3.9M
Freedom Medical Supply LLC	NV	Durable Medical Equipment & Medical Supplies	$0	$3.9M
Nadhc At Eastern, Inc.	NV	Adult Day Care Clinic/Center	$0	$3M
Autism And Brain Institute Inc	NV	Occupational Therapist	$0	$1.6M
Helga Uzcategui	NV	Ophthalmology Physician	$563.9K	$0
Digestive Disease Center-green Valley	NV	Ambulatory Surgical Clinic/Center	$449.4K	$0

Nasim Daoud — Billing Profile & Reimbursement Data

Sign up for Nasim Daoud — Billing Profile & Reimbursement Data policy alerts

Nasim Daoud — Billing Profile & Reimbursement Data

Sign up for Nasim Daoud — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References